3BDO
Based on 21 publication(s) in Google Scholar
3BDO is a IFITM3 modulator and mTOR activator with antiviral and autophagy-inhibiting effects. 3BDO exhibits inhibitory activity against porcine coronaviruses. 3BDO increases the protein abundance of IFITM3, inhibits virus-cell membrane fusion, and blocks viral entry. 3BDO inhibits the entry of transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and porcine respiratory coronavirus into host cells. 3BDO can be used for research on porcine coronavirus infection.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 890405-51-3
- Formula: C18H17NO5
- Molecular Weight:327.33
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Antiviral Compound Library
HY-L027
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Glucose Metabolism Compound Library
HY-L092
-
Antidepressant Compound Library
HY-L108
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) 3BDO
More- Nat Commun. 2024 Aug 9;15(1):6810. [Abstract]
- Cell Death Differ. 2023 Jul;30(7):1695-1709. [Abstract]
- EBioMedicine. 2023 Feb:88:104444. [Abstract]
- Cancer Lett. 2024 Aug 6:217161. [Abstract]
- Acta Biomater. 2018 Nov:81:278-292. [Abstract]
- J Transl Med. 2025 Feb 21;23(1):219. [Abstract]
- Appl Mater Today. 2021, 101066.
- Int J Mol Med. 2020 Nov;46(5):1816-1826. [Abstract]
- Biochem Pharmacol. 2020 Aug;178:114038. [Abstract]
- J Ethnopharmacol. 2025 Jul 29:120333. [Abstract]
- J Ethnopharmacol. 2025 Jan 30;337(Pt 2):118872. [Abstract]
- Respir Res. 2024 May 20;25(1):215. [Abstract]
- Front Pharmacol. 2020 Nov 11;11:580407. [Abstract]
- Aging (Albany NY). 2021 Mar 10;13(7):9542-9565. [Abstract]
- J Virol. 2024 Dec 6:e0144924. [Abstract]
- Neurochem Res. 2022 Dec;47(12):3777-3791. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2024 Sep 1;327(3):G317-G332. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Vet Microbiol. 2026 Jan 27:315:110907. [Abstract]
- Arch Physiol Biochem. 2024 Sep 3:1-10. [Abstract]
- University of Liege. 2024.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
|
mTOR |
3BDO (20 μM; 19 h) potently inhibits TGEV infection in porcine intestinal organoid monolayers with an IC50 of 14.6 μM and a high selectivity index of 87.67, indicating an acceptable safety margin[1].
3BDO (15-60 μM; 18 h) inhibits TGEV infection in porcine intestinal organoid monolayers in vitro in a dose-dependent manner, reducing viral protein levels, viral titers, and viral fluorescence signal[1].
3BDO (60 μM) restricts TGEV infection in ST cells and porcine intestinal organoid monolayers by specifically targeting viral entry, with no effect on viral inactivation, attachment, replication, or release[1].
3BDO blocks TGEV entry in ST cells by specifically enhancing IFITM3 protein abundance, as knockdown of IFITM3 eliminates its antiviral activity[1].
3BDO blocks PRCV entry in ST cells and PEDV entry in PK-15 cells by enhancing IFITM3 protein abundance, as knockdown of IFITM3 eliminates its antiviral activity against both viruses[1].
In an autophagy induction model, 3BDO inhibits the Rapamycin (HY-10219)-induced increase in the number of MAP1LC3B puncta, the elevation of MAP1LC3B-II levels, and the reduction of SQSTM1 protein levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
3BDO significantly reduces serum IL-6 and IL-8 levels in apoE-/- mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 890405-51-3
-
Appearance Solid-Liquid Mixture
-
Molecular Weight 327.33
-
Formula C18H17NO5
-
Color Off-white to light yellow
-
SMILES
O=C1OC(COC2=C([N+]([O-])=O)C=CC=C2)CC1CC3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma. [Abstract]2024 Aug 9;15(1):6810. PMID: 39122682
3BDO purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 9;15(1):6810. [Abstract]
Effect on cell viability of NCI-H929 cells infected with scramble or PPP1R15B-targeting shRNAs after treatment with the mTOR activator 3BDO (20 µM) for 48 hours.
-
Cell Death Differ
AF9 targets acetyl-modified STAT6 to diminish purine metabolism and accelerate cell apoptosis during metastasis. [Abstract]2023 Jul;30(7):1695-1709. PMID: 37308587 -
EBioMedicine
F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. [Abstract]2023 Feb:88:104444. PMID: 36709580 -
Cancer Lett
Platelets promote primary hepatocellular carcinoma metastasis through TGF-β1-mediated cancer cell autophagy. [Abstract]2024 Aug 6:217161. PMID: 39117067 -
Acta Biomater
Graphene oxide induces p62/SQSTM-dependent apoptosis through the impairment of autophagic flux and lysosomal dysfunction in PC12 cells. [Abstract]2018 Nov:81:278-292. PMID: 30273743
3BDO purchased from MedChemExpress. Usage Cited in: Acta Biomater. 2018 Nov:81:278-292. [Abstract]
PC12 cells are pretreated with 740-YP (30 μM), or SC79 (13.7 μM), or 3BDO (100 μM) for 1 h, and for the duration of GO (50 μg/mL) incubation for 24 h. LC3 turnover is detected by western blotting.
-
J Transl Med
HMGCL activates autophagy in osteosarcoma through β-HB mediated inhibition of the PI3K/AKT/mTOR signaling pathway. [Abstract]2025 Feb 21;23(1):219. PMID: 39985081 -
-
Int J Mol Med
Autophagy inhibition enhances the inhibitory effects of ursolic acid on lung cancer cells. [Abstract]2020 Nov;46(5):1816-1826. PMID: 32901853 -
Biochem Pharmacol
Ginsenoside Rh4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting AKT in esophageal cancer. [Abstract]2020 Aug;178:114038. PMID: 32422139 -
J Ethnopharmacol
Licochalcone A promotes autophagy to ameliorate NAFLD by inhibiting the mTOR and regulating ULK1/Beclin1/VPS34 pathway. [Abstract]2025 Jul 29:120333. PMID: 40744422 -
J Ethnopharmacol
Xiao-Er-Kang-Du capsules regulate autophagy against the influenza B virus (Victoria strain) through the mTOR/ULK1/Beclin1/VPS34 pathway. [Abstract]2025 Jan 30;337(Pt 2):118872. PMID: 39366496 -
Respir Res
Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. [Abstract]2024 May 20;25(1):215. PMID: 38764025 -
Front Pharmacol
CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]2020 Nov 11;11:580407. PMID: 33343350 -
Aging (Albany NY)
Gastrodin ameliorates learning and memory impairment in rats with vascular dementia by promoting autophagy flux via inhibition of the Ca2+/CaMKII signal pathway. [Abstract]2021 Mar 10;13(7):9542-9565. PMID: 33714957 -
J Virol
Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy. [Abstract]2024 Dec 6:e0144924. PMID: 39641621 -
Neurochem Res
3BDO Alleviates Seizures and Improves Cognitive Function by Regulating Autophagy in Pentylenetetrazol (PTZ)-Kindled Epileptic Mice Model. [Abstract]2022 Dec;47(12):3777-3791. PMID: 36243819 -
Am J Physiol Gastrointest Liver Physiol
Revitalizing gut barrier integrity: miR-192-5p's role in enhancing autophagy via Rictor in enteritis. [Abstract]2024 Sep 1;327(3):G317-G332. PMID: 38954822 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Vet Microbiol
Intestinal organoids screening reveals: 3BDO as an inhibitor of porcine coronaviruses entry by targeting IFITM3. [Abstract]2026 Jan 27:315:110907. PMID: 41712999 -
Arch Physiol Biochem
Mangiferin prevents glucolipotoxicity-induced pancreatic beta-cell injury through modulation of autophagy via AMPK-mTOR signaling pathway. [Abstract]2024 Sep 3:1-10. PMID: 39225043 -
Solvent & Solubility
DMSO : ≥ 100 mg/mL (305.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 20 mg/mL (61.10 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Total protein is obtained from HUVECs by using of IP lysis buffer after treatment with rapamycin (10 μM), 3BDO (60 μM) or both for 6 h. After centrifuging at 4°C, the supernatant is collected and incubated with protein A/G agarose beads and TIA1 antibody or normal mouse IgG as a control at 4°C overnight. The beads are washed 3 times with IP lysis buffer and then eluted with 4×SDS loading buffer. Ser phosphorylation is detected by western blot assay with Ser phosphorylation antibody[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
HUVECs are isolated from umbilical cords and cultured in M199 medium with 20% (v/v) fetal bovine serum and 10 IU/mL fibroblast growth factor 2 (FGF2) in a humidified incubator at 37°C with 5% CO2. Cells up to passage 10 are used for experiments. When HUVECs are grown to 80% confluency, HUVECs are treated with DMSO or 60 µM 3BDO for 24 h, then total RNA is extracted[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Male apoE-/- mice (8 weeks old) are used in this study. ApoE-/- mice are fed an atherogenic diet (containing 21% fat and 0.15% cholesterol). To avoid the potential confounding effects of variation among batches of diet, a single batch is reserved and used throughout the experiment. Mice at 20 weeks older are divided into 3 groups for treatment (n=8 mice/group) for 8 weeks: control (DMSO), low-dose 3BDO (50 mg/kg/d; 3BDO-L) and high-dose 3BDO (100 mg/kg/d; 3BDO-H). The body weight of mice is measured every week during 3BDO injection. Blood samples are taken from the inferior vena cava, and animals are killed by exsanguination[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[2]. Ge D, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014 Jun;10(6):957-71. [Content Brief]
[3]. Peng N, et al. An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E-/- mice. Sci Rep. 2014 Jul 1;4:5519. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 3.0550 mL | 15.2751 mL | 30.5502 mL | 76.3755 mL |
| 5 mM | 0.6110 mL | 3.0550 mL | 6.1100 mL | 15.2751 mL | |
| 10 mM | 0.3055 mL | 1.5275 mL | 3.0550 mL | 7.6376 mL | |
| 15 mM | 0.2037 mL | 1.0183 mL | 2.0367 mL | 5.0917 mL | |
| 20 mM | 0.1528 mL | 0.7638 mL | 1.5275 mL | 3.8188 mL | |
| 25 mM | 0.1222 mL | 0.6110 mL | 1.2220 mL | 3.0550 mL | |
| 30 mM | 0.1018 mL | 0.5092 mL | 1.0183 mL | 2.5459 mL | |
| 40 mM | 0.0764 mL | 0.3819 mL | 0.7638 mL | 1.9094 mL | |
| 50 mM | 0.0611 mL | 0.3055 mL | 0.6110 mL | 1.5275 mL | |
| 60 mM | 0.0509 mL | 0.2546 mL | 0.5092 mL | 1.2729 mL | |
| DMSO | 80 mM | 0.0382 mL | 0.1909 mL | 0.3819 mL | 0.9547 mL |
| 100 mM | 0.0306 mL | 0.1528 mL | 0.3055 mL | 0.7638 mL |
Powered by Bioz